Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
[2] That is more "real life" than best case
Users who experience persistent diarrhea, vomiting, or severe nausea are at higher risk because of dehydration
Treatment should be stopped, and immediate medical attention sought if severe, persistent abdominal pain occurs (which may radiate to the back), with or without vomiting
Survodutide Dosing The SYNCHRONIZE Phase 3 trials use a modified escalation protocol designed to improve tolerability compared to Phase 2: Starting dose: Low dose with gradual increases Escalation: Extended titration period with flexibility Target doses: 3.6mg or 6.0mg weekly (SYNCHRONIZE-1) Pause option: Ability to temporarily stop dosing for GI symptoms Time to maintenance: Extended to reduce side effects The inclusion of a pause option in Survodutide trials reflects lessons learned from Phase 2 about the importance of allowing patient-directed tolerance management
While both target GLP-1 receptors, Tirz also activates GIP receptors, making it a dual agonist
